FGFR3-TACC3 (F3T3) fusions are seen in 3.1–11.7% of glioblastoma (GBM) cases with better survival [1, 4, 5, 7–9]. We endeavored to characterize methylation profles in detail, using a cohort of 79 F3T3-positive GBMs from 71 patients (seven patients with primary and recurrent tumor resections, Table S1). Compared to gliomas without a docu mented fusion, dimensionality reduction showed that F3T3- positive GBMs nested predominantly to GBM-mesenchymal and RTK-II subclasses (Fig. 1a). Transcriptomic analysis on 9 F3T3-positive and 31 negative patients (Fig. 1b) confrmed a previous fnding of activated mitochondrial activity and altered vascular activity [2, 6].
Wu, Z., Lopes Abath Neto, O., Bale, T.A., Benhamida, J., Mata, D., Turakulov, R., et al. (2022). DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival. ACTA NEUROPATHOLOGICA, 144(1), 155-157 [10.1007/s00401-022-02430-7].
DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival
Giannini, Caterina;
2022
Abstract
FGFR3-TACC3 (F3T3) fusions are seen in 3.1–11.7% of glioblastoma (GBM) cases with better survival [1, 4, 5, 7–9]. We endeavored to characterize methylation profles in detail, using a cohort of 79 F3T3-positive GBMs from 71 patients (seven patients with primary and recurrent tumor resections, Table S1). Compared to gliomas without a docu mented fusion, dimensionality reduction showed that F3T3- positive GBMs nested predominantly to GBM-mesenchymal and RTK-II subclasses (Fig. 1a). Transcriptomic analysis on 9 F3T3-positive and 31 negative patients (Fig. 1b) confrmed a previous fnding of activated mitochondrial activity and altered vascular activity [2, 6].I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
